Who asks: the clinical safety lead at Calder Bay Pharma, a fictional company.
Why: a drug safety associate on a clinical trial must show they can take a serious adverse event form from a blinded study to an assessment ready for the safety physician, on time.
The data: the SAE form on the left for subject 014-0087 in study CBP-TLV-301, and the Teluvant Investigator's Brochure (Reference, then Products).
What done looks like: a worksheet with the seriousness criterion, expectedness against the Investigator's Brochure, whether it is a suspected unexpected serious adverse reaction, what happens to the blind, the WHO-UMC category, day 0 and the due date, the narrative order and the follow-up questions.
A project in eight steps on one SAE form from a blinded trial. Each step adds to your worksheet; by the end you have the assessment a safety physician would sign off.
One rule you meet here for the first time. ICH E2A: when a serious adverse reaction in a blinded trial is judged reportable on an expedited basis, the sponsor breaks the blind for that subject only, even if the investigator has not, and keeps the blind for the people who will analyse the study. Events on placebo usually do not count as adverse drug reactions for expedited reporting.